Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including I...
Guardado en:
Autores principales: | , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6e1a90c822834423a44782c190dfd876 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:6e1a90c822834423a44782c190dfd876 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:6e1a90c822834423a44782c190dfd8762021-12-02T06:29:08ZPotential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis1176-63281178-2021https://doaj.org/article/6e1a90c822834423a44782c190dfd8762010-09-01T00:00:00Zhttp://www.dovepress.com/potential-short-term-use-of-oral-cladribine-in-treatment-of-relapsing--a5342https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing-remitting MS. Cladribine, also known as 2-chlorodeoxyadenosine, is a synthetic adenosine deaminase-resistant purine nucleoside analog that preferentially depletes lymphocyte subpopulations. This sustained effect on lymphocytes is advantageous for patients with MS. CLARITY (CLAdRIbine Tablets Treating MS OrallY), a Phase III trial, has demonstrated that short-term oral cladribine decreases relapse rates and risk of disability progression in comparison with placebo. Cladribine was well tolerated in the study, with the most common adverse effects being headache, nausea, upper respiratory tract infections, and lymphocytopenia. An ongoing study is evaluating the efficacy and safety of the combination of oral cladribine and IFN-β products. A further ongoing study is examining the use of oral cladribine in clinically isolated syndrome and time to conversion to MS. Although the results of CLARITY are promising, the exact role of oral cladribine may be better defined with the completion of ongoing studies.Keywords: cladribine, multiple sclerosis, relapsing-remitting, oral, disease-modifying therapy Julie A MurphyJacklyn A HarrisAndrew J CrannageDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 619-625 (2010) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Julie A Murphy Jacklyn A Harris Andrew J Crannage Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis |
description |
Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing-remitting MS. Cladribine, also known as 2-chlorodeoxyadenosine, is a synthetic adenosine deaminase-resistant purine nucleoside analog that preferentially depletes lymphocyte subpopulations. This sustained effect on lymphocytes is advantageous for patients with MS. CLARITY (CLAdRIbine Tablets Treating MS OrallY), a Phase III trial, has demonstrated that short-term oral cladribine decreases relapse rates and risk of disability progression in comparison with placebo. Cladribine was well tolerated in the study, with the most common adverse effects being headache, nausea, upper respiratory tract infections, and lymphocytopenia. An ongoing study is evaluating the efficacy and safety of the combination of oral cladribine and IFN-β products. A further ongoing study is examining the use of oral cladribine in clinically isolated syndrome and time to conversion to MS. Although the results of CLARITY are promising, the exact role of oral cladribine may be better defined with the completion of ongoing studies.Keywords: cladribine, multiple sclerosis, relapsing-remitting, oral, disease-modifying therapy |
format |
article |
author |
Julie A Murphy Jacklyn A Harris Andrew J Crannage |
author_facet |
Julie A Murphy Jacklyn A Harris Andrew J Crannage |
author_sort |
Julie A Murphy |
title |
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis |
title_short |
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis |
title_full |
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis |
title_fullStr |
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis |
title_full_unstemmed |
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis |
title_sort |
potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis |
publisher |
Dove Medical Press |
publishDate |
2010 |
url |
https://doaj.org/article/6e1a90c822834423a44782c190dfd876 |
work_keys_str_mv |
AT julieamurphy potentialshorttermuseoforalcladribineintreatmentofrelapsingremittingmultiplesclerosis AT jacklynaharris potentialshorttermuseoforalcladribineintreatmentofrelapsingremittingmultiplesclerosis AT andrewjcrannage potentialshorttermuseoforalcladribineintreatmentofrelapsingremittingmultiplesclerosis |
_version_ |
1718399875779919872 |